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Cellular therapies with CD4+ T regulatory cells (Tregs) hold promise of efficacious treat-
ment for the variety of autoimmune and allergic diseases as well as posttransplant com-
plications. Nevertheless, current manufacturing of Tregs as a cellular medicinal product 
varies between different laboratories, which in turn hampers precise comparisons of the 
results between the studies performed. While the number of clinical trials testing Tregs 
is already substantial, it seems to be crucial to provide some standardized characteris-
tics of Treg products in order to minimize the problem. We have previously developed 
reporting guidelines called minimum information about tolerogenic antigen-presenting 
cells, which allows the comparison between different preparations of tolerance-inducing 
antigen-presenting cells. Having this experience, here we describe another minimum 
information about Tregs (MITREG). It is important to note that MITREG does not dictate 
how investigators should generate or characterize Tregs, but it does require investigators 
to report their Treg data in a consistent and transparent manner. We hope this will, 
therefore, be a useful tool facilitating standardized reporting on the manufacturing of 
Tregs, either for research purposes or for clinical application. This way MITREG might 
also be an important step toward more standardized and reproducible testing of the 
Tregs preparations in clinical applications.
Keywords: minimum information model, t  regulatory cells, immunotherapy, good manufacturing practice, cell 
therapy, immune tolerance
intRoDUCtion
T  regulatory cells (Tregs) are dominant cellular compounds 
of the immune system protecting the body from autoimmune 
reactions. These cells are also involved in imposing tolerance 
to alloantigens such as transplanted allogeneic cells and tissues 
(1–5). For all these reasons, several Treg-based therapeutics 
are being tested in clinical trials as a prophylaxis or treat-
ment of autoimmune diseases, graft-versus-host disease after 
hematopoietic stem cell transplants or rejections after solid 
organ transplants (6). The list of potential applications in the 
future is even wider. At the same time, manufacturing of Tregs 
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for preclinical and clinical experiments varies considerably 
between different centers, which significantly diminishes pos-
sible comparisons between the trials. For this reason, future 
development of these therapies is hampered as it happens that 
the available results from different trials are contradictive. The 
specificity of cellular products makes it difficult to verify the 
results in huge multicentre trials and therefore better stand-
ardization of early-phase trials as well as cellular products 
themselves might facilitate the progress in this promising 
branch of medicine.
We propose here a tool for standardization of Tregs studies 
designed on the basis of so-called minimum information mod-
els (MIMs). These models have gained increasing popularity 
among scientists as they enable the interpretation of reported 
data, comparison between data from different studies and 
facilitate experimental reproducibility (7, 8). MIMs provide 
mechanisms that all laboratories report at least the key facts 
about their analysis in a clear and consistent manner, allow-
ing a comparison across the whole field. Our consortium has 
already designed the MIM called minimum information about 
tolerogenic antigen-presenting cells (MITAP). This is a reporting 
framework that makes transparent differences and similarities 
of different tolerogenic antigen-presenting cells (tolAPC) (9). 
It provides minimum reporting guidelines for the production 
process of tolAPC used in preclinical and/or clinical studies. 
We have followed the MITAP experience and designed a MIM 
for the manufacture of Tregs. We call it minimum information 
about T regulatory cells (MITREG). MITREG will be a useful 
resource for investigators reporting their data on the use of 
in vitro expanded natural Tregs or induced Tregs in preclinical 
models or clinical trials.
MEtHoDs
setting Up MitREG: Community Building 
and initial analysis
The community was mainly built on the experience of our 
completed MITAP initiative. For several years now, we have been 
working together in the field of tolerogenic cellular therapies 
under the umbrella of the consortium AFACTT (action to focus 
and accelerate cell-based tolerance-inducing therapies—http://
www.afactt.eu/). It brings together European scientists and clini-
cians with the aim of jointly addressing issues related to the trans-
lation and clinical application of these new treatments. Having 
the experience of MITAP, we used this document as a template 
to describe Treg therapies. For MITREG, we also tried to extend 
the initiative beyond Europe and invited scientists working on 
tolerogenic cellular therapies from around the world. This way we 
ensured a broadly reflective discussion taking into account vari-
ous opinions and current practices of many laboratories within 
the discipline.
The work on this MITREG document covered a series of 
“exercises” that provided some initial data. Like for MITAP, the 
exercises aimed at gathering “terms” in order to acquire basic 
vocabulary in use within the community. The first, so-called 
“sticky-note” exercise performed at several AFACTT meetings 
assumed that each participant wrote a term on a sticky-note; these 
were then collated and clustered on a wall by the whole group, 
identifying synonyms and related terms. Second, we used the 
MITAP template to incorporate the collected terms and created 
an initial version of MITREG. This document underwent several 
rounds of face-to-face and online consultations with AFACTT 
members to improve its clarity. Internally agreed version was 
circulated to external specialists in the field. This external feed-
back was collected and implemented in the final version of the 
MITREG document. Finally, we used the existing literature to 
obtain a picture of how well the required information has been 
described in published articles.
REsUlts
overview of the MitREG Document
The design of the MITREG document followed the concept 
of MITAP, which facilitated the whole process. It describes 
the manufacturing of Treg products in a chronological way. 
The document is divided into four sections highlighting criti-
cal points of the process and regulatory issues. The document 
describes the details that should be provided by investigators, 
which would allow other researchers to repeat the process. It 
also advises on the use of existing taxonomies and databases to 
provide the information in a uniform manner, and it suggests the 
use of other MIMs where appropriate. The full MITREG docu-
ment can be found on archive.org (http://w3id.org/ontolink/
mitreg) and it is also included in the Appendix A (MITREG 
document).
section 1: Cells at the start of the 
Procedure
This section describes characteristics of the biological material 
before it undergoes any manipulation. There are five subparts ask-
ing for (a) essential information about the donor, (b) source of the 
cells, (c) the methods used to separate Tregs, (d) the phenotype 
after separation, and (e) the number of Tregs after separation.
section 2: Expansion/Differentiation
This section describes the protocol that has been used to expand 
or differentiate Tregs. The specificity of Tregs was a challenge here 
as different subsets can be obtained with a wide range of methods. 
Tregs can be either isolated and optionally expanded or can be 
induced from naive precursors. There are five subsections giving 
details on (a) preculture conditions, (b) culture conditions, (c) 
the protocol used to expand or differentiate cultured Tregs, (d) 
stimuli used during the process, and (e) the way Tregs are stored 
immediately after expansion/differentiation.
section 3: Cells after Expansion/
Differentiation
This section describes the characteristics of Tregs after the expan-
sion or differentiation. It is mainly focused on the phenotype of 
the final Treg product as well as its suppressive activity verified in 
any form of functional assay. It also documents the cell yield from 
the entire process and, if the product is for clinical use or testing 
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of adoptive transfer in animals, the details on administration of 
the cells to the recipient.
section 4: about the Protocol
This final section describes remaining details of the experimental 
or clinical protocol such as primary or secondary goals as well as 
regulatory issues such as adherence to particular acts or directives 
including compliance with good practice requirements (GCP, 
GLP, or GMP guidelines). Finally, the name and contact details 
of the corresponding author(s) must be provided.
The MITREG document is accompanied by a handy checklist 
to assist investigators in ensuring that all the relevant detail is pro-
vided before submitting their manuscripts for publication. The 
checklist can be found at archive.org (http://w3id.org/ontolink/
mitreg) and is also included in the Appendix B (MITREG 
checklist).
Prevalence of MitREG Data in Extant 
Published articles
The purpose of the MITREG document is to ensure that authors 
provide sufficient basic information about their production pro-
tocol. An implicit assumption is that currently some or all of this 
information is not being routinely described. To test this assump-
tion, we reviewed a number of articles about Treg products and 
for each we determined whether it included data described in the 
MITREG document.
In detail, 19 Treg articles were selected (predominantly from 
members of AFACTT or from researchers well known in the 
field) and read in detail. The articles are given chronologically 
in the references but the order in Figure  1 is different and 
anonymized (10–28). For each section of MITREG, we deter-
mined whether the information required was directly stated 
in the article (or referenced) (Figure 1: green squares), partly 
stated in the article (Figure  1: yellow triangles), not present 
at all (Figure  1: red circles), or whether information was not 
present due to lack of relevance for the publication (Figure 1: 
gray circles). For example, section 1-ai of MITREG describes 
the species used in the experimental setup. An article with the 
phrase “human” or “Homo sapiens” would fall into the first 
category (included in the publication). However, when mice are 
used and only the species is mentioned: “mouse” or “Mus mus-
culus,” but not the strain, it would fall into the second category 
(included but details missing). Many articles do not describe 
their experimental methodology, but instead refer to another 
article (“as described previously”); in this case, we checked the 
article up to two references deep and if found, the information 
was considered as “present” (Figure  1: green squares), if not 
it was considered as “not present” (Figure 1: red circles). This 
work was performed by four independent scientists with experi-
ence in the field.
Results are shown in Figure 1. This figure shows that in some 
sections like the species, characteristics, ethics, and cell dose 
transferred sections, reporting is good with almost all revised 
articles describing these. However, other sections are often very 
poorly reported. For example, storage of cells, anticoagulant used 
and the number/viability of cells after each separate step are not 
described in most articles. Moreover, important information 
(container type, concentration of cells) to repeat the performed 
experiments is missing in almost all articles.
sustainability
We have taken particular care to consider the issues of 
digital sustainability for MITREG. A well-known problem with 
resources linked with URLs given in articles is that URLs are 
often lost over time: around a 25% loss 3  years after publica-
tion (29). We have, therefore, specifically addressed this issue 
by use of a stable identifier space; the MITREG document and 
checklist are hosted by archive.org, an organization committed 
to long-term digital preservation. In addition, we have used a 
permanent identifier (http://w3id.org/ontolink/mitreg) thereby 
providing a redirection-step.
Resources are available in a number of formats: both PDF and 
Word for manipulability, but also a simple HTML representation, 
ensuring vendor-neutrality and future-proofing, in so far as this 
is possible.
DisCUssion
Minimum information models aid investigators by providing a 
specific guideline of what is required to interpret and compare 
experimental findings. Furthermore, reporting guidelines will 
facilitate independent validation of published results, a funda-
mental precept of scientific research. This is to our knowledge 
the first proposal of a minimum information standard on the 
description of experimental as well as clinical manufacturing and 
application of Tregs. The generation of MITREG was initiated by 
members of the European AFACTT consortium to fill a recog-
nized gap in data reporting standards in the Treg community. 
MITREG was realized with the help of key international players 
in the Treg field.
Nine years after the first-in-man report, there are currently 
close to 30 recruiting or ongoing clinical trials administering Tregs 
in autoimmune settings, inflammatory diseases, transplantation 
and graft-versus-host disease (6). Clinical grade reagents for Treg 
isolation by magnetic activated cell sorting have become available 
to the growing community and off the shelf products and GMP-
compatible fluorescence-based cell sorting is currently been 
available from multiple manufacturers of novel closed system 
devices, further increasing the diversity of isolation techniques 
(30). Given the low frequency of Tregs in the periphery, most 
clinical applications require an in vitro cell expansion culturing 
step classifying them as advanced therapy medicinal products. A 
growing number of culturing methods are being developed and 
published aiming at Treg induction, enhanced ex vivo expansion, 
alloreactivity and more recently, the implementation of specific 
T cell receptors or chimeric antigen receptors (17, 18, 25, 31–39). 
We are thus at a point where protocol diversity is growing expo-
nentially, emphasizing the necessity to harmonize reporting regi-
mens as a prerequisite of reproducibility and quality assurance. 
By analyzing extant articles according to the MITREG document 
(Figure 1), it also becomes clear that there is a big gap in what 
is currently being reported and what the community considers 
important and wants to receive in a Treg production/expansion 
fiGURE 1 | Agreement of published T regulatory cell (Treg) articles with the minimum information about T regulatory cell (MITREG) document. Graph showing the 
results of a total of 19 Treg articles (10–28). The order in the figure is anonymized and different from that in the references. MITREG data directly stated in the article 
(■ green squares), partly stated in the article (▲ yellow triangles), not present at all (● red circles), or not present as it was not relevant for the publication (● gray 
circles).
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aPPEnDiX a
MiniMUM infoRMation foR 
t REGUlatoRY CElls (MitREG)
introduction
The purpose of this document is to enable the description of the 
generation of T  regulatory cell (Treg) products for therapeutic 
application or experimental usage. It was designed to suit reports 
using endogenous, induced, antigen-specific, and polyclonal 
freshly isolated and expanded Tregs.
This document is split into four sections, each describing a 
different aspect of the process. Not all sections will be relevant to 
all Treg products.
Information in some sections of this document may be 
covered by other Minimum Information documents, or defined 
vocabularies. For example, flow cytometry is described in 
MIFlowCyt,1 microarray data by MIAME,2 T-cell assays by 
MIATA,3 and production of standardized tolerogenic antigen-
presenting cells by MITAP,4 Authors are encouraged to use these 
resources as appropriate.
Use of terminology
The key words “must,” “should,” and “may” in this document are 
to be interpreted as follows:
must: this word means that the information is an absolute 
requirement. Failure to provide this information is in strict viola-
tion of the specification.
EXAMPLE: the species and the source of the cell material are 
required for all experiments.
should: this word means that there may exist valid reasons for 
particular protocols to not provide these data, but that these data 
need to be provided if it is relevant to the protocol.
EXAMPLE: if the Tregs were generated or enriched using an antigen 
then this must be described, although there may be protocols where 
polyclonal Tregs are applied.
may: this word means that the data are optional and do not need 
to be included, but can be provided.
EXAMPLE: the health or age of the organism can be provided, but 
there may be protocols where this is not assessed, even though it 
could be.
These definitions are modified from RFC 2119 (https://tools.ietf.
org/html/rfc2119).
1 http://flowcyt.sourceforge.net/miflowcyt/
2 http://fged.org/projects/miame/
3 http://miataproject.org
4 https://doi.org/10.7717/peerj.2300
(1) Cells at the start of procedure
This section describes the characteristics and state of the cells 
used in the procedure prior to any form of cell manipulation 
processes such as cell expansion and/or differentiation.
(a) Essential information about the donor
(i) Species and strain
The taxonomy of the organism from which the cells originated. 
You must use names according to the NCBI Taxonomy.5 If the 
strain of the species is known, you should indicate this.
EXAMPLE: Homo sapiens/human; Mus musculus, Rag−/−γc−  
(B6, H-2b)
(ii) Characteristics of the organism
Include information about the organism from which the cells 
originated that is not adequately described by the species/strain 
information. This may include details of their health, age, sex, or 
any treatments or environmental conditions to which they have 
been exposed to (e.g., medication). You may also include infor-
mation that is specific to your laboratory, such as an individual 
identifier number. If you have purchased experimental animals 
(e.g., BALB/c mice) or tissues (e.g., human bone marrow) you 
should indicate the source of purchase.
EXAMPLE: healthy/volunteer/male/6-weeks-old/male/BALB/c 
mice/purchased from Charles River (Margate England)
(b) Source of cell material
The organ, tissue, or fluid from which the cells have been isolated 
must be stated. If you use a blood product you should state the 
product and the source (e.g., hospital department, blood bank) 
from where it was obtained. You should use terminology from 
Uberon,6 or the Foundational Model of Anatomy.7 You should 
also indicate the quantity of the sample by mass or volume, 
and, if applicable, which anti-coagulant was used. Additional 
details must be included if the source material was derived from 
cryopreserved samples (e.g., umbilical cord blood). This would 
include the methods and duration of storage and initial cell 
counts. The statement on use/ethics committee approval/written 
informed consent MUST be included.
EXAMPLE: apheresis/buffy coat/bone marrow aspirate/peripheral 
blood, Sanquin blood supply; 250 ml; EDTA
(c) Cell separation process
(i) Cell handling and labeling
The methodology used to extract the cells from the source mate-
rial must be stated. You should also indicate the time between cell 
material retrieval and start of the isolation process. You should 
indicate how the tissue was kept during this time, including the 
5 http://www.ncbi.nlm.nih.gov/taxonomy/
6 http://www.uberon.org 
7 http://fme.biostr.washington.edu/FME
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temperature and you may indicate the container and fluid. You 
must indicate cell labeling procedures, including characteristics 
and source of labeling buffers and reagents. Other details, such as 
cell suspension volume and concentration, incubation tempera-
ture and washing steps should be included.
EXAMPLE: apheresis products were stored overnight at 4°C; 
Tregs were enriched by magnetic-activated cell sorting (MACS® 
Technology); Cells were labeled with anti-CD8-coated magnetic 
beads (CliniMACS® CD8 Reagent, Miltenyi Biotec) in 95  ml of 
PBS containing 1 mmol/l EDTA and 0.5% human albumin (PBS/
EDTA buffer, Miltenyi Biotec) for 30 min at room temperature on 
an orbital shaker.
(ii) Cell separation equipment and process
The equipment (e.g., AutoMACS®, CliniMACS®, Aria III™ 
Fluorescence Activated Cell Sorter) and process used to enrich 
for the cells of interest should be stated. The presence of the target 
population in the starting material should be described.
EXAMPLE: anti-CD8 bead-labeled cells were resuspended in 
100 ml of PBS/EDTA/0.5% HA. CD8+ cells were depleted with the 
use of the 2.1 depletion program on the CliniMACS® Cell Separation 
Device (Miltenyi Biotec).
(d) Phenotype
Characteristics of the cells that have been isolated should be 
described and how this has been determined. Where only a 
proportion of cells in the population display a characteristic, you 
should indicate the percentage.
(i) Cell surface and intracellular markers
Identifying molecules that are, or are not, expressed by the 
cells on their surface or intracellularly is useful. You should 
describe: (1) what you measured, (2) the methodology used for 
the measurement (including information on reagents; if using 
mAbs, information on clonotype, conjugate, and manufacturer 
must be provided), (3) whether the cells received a stimulus 
and for how long before the measurement was carried out, 
and (4) the method used to set marker or population positivity 
(e.g., fluorescence minus one method). You should use cluster 
of differentiation (CD) names when available (e.g., use CD62L 
instead of the alternative name L-selectin)—a full list of regularly 
updated CD numbers can be found on the website run by the 
HCDM8 (human cell differentiation molecules). Otherwise, you 
may use databases, e.g., Uniprot9 for proteins and ChEBI10 for 
non-protein organic molecules.
EXAMPLE: FOXP3 (PE-Cy7, clone PCH101, eBioscience) expres-
sion was measured directly after cell isolation by intracellular stain-
ing using the Foxp3/Transcription Factor Staining Buffer Set from 
eBioscience. Percentage of CD4+CD25highCD127−/lowFOXP3+lin−do
ublet− Treg cells was determined by flow cytometry (FACS Canto 
8 http://www.hcdm.org/
9 http://www.uniprot.org/
10 https://www.ebi.ac.uk/chebi/
II™, Becton Dickinson). After the isolation, 98.0% (median, range 
97–99.5%) of the cells presented this phenotype.
(ii) Secreted molecules
Molecules that are, or are not, secreted by the cells are useful to 
identify. These include cytokines (e.g., IL-10) and other soluble 
mediators. You should describe: (1) what you measured, (2) 
If using Abs, clone, conjugate and source of all antibodies and 
reagents used must be provided, (3) the methodology used for 
measurement, (4) cell density/milliliter of medium and plastic 
ware (e.g., 96 w round/flat bottom), (5) when supernatant was 
collected for cytokine concentration measurement, and (6) 
whether the cells received a stimulus and for how long before the 
measurement was carried out.
EXAMPLE: IFN-γ; ELISA; supernatant after 24 h of unstimulated 
cell culture.
(iii) Epigenetic modifications
Epigenetic modification relevant to the characteristics should be 
described if determined. Method of detection DNA demethyla-
tion should be clearly described.
EXAMPLE: the mean percentage of demethylated TSDR of the foxp3 
gene in the Treg population was 7% (Epiontis, Berlin, Germany).
(iv) Specificity
Polyclonal or antigen-specific, especially genetic modifications to 
manipulate specificity should be described. You should describe: 
(1) what is the specificity of the cells, (2) the methodology used to 
obtain the specificity, and (3) the methodology used to confirm 
the specificity. To describe the specificity of your cells, you should 
use CD names when available (e.g., use CD19 instead of the alter-
native name B4)—a full list of regularly updated CD numbers 
can be found on the website run by the HCDM8 (human cell 
differentiation molecules). Otherwise, you may use databases, 
e.g., http://hla.alleles.org, for HLA alleles, Uniprot9 for proteins 
and ChEBI10 for non-protein organic molecules describing the 
targets for your cells.
EXAMPLE: HLA-A2-specific CAR (A2-CAR) Tregs were generated 
with lentiviral vectors encoding an HLA-A2-specific CAR by clon-
ing and sequencing the heavy- and light-chain variable regions of 
the mAb and fusing the resulting scFv to portions of CD8, CD28, 
and CD3ζ in a second-generation CAR structure. Tetramers made 
from HLA-A2 were used to confirm the specificity of binding the 
cells to HLA-A2.
(e) Cell numbers
(i) Absolute cell number
You should indicate the total number of cells present after extrac-
tion, and how they have been counted.
EXAMPLE: 980 × 106 cells as determined by Coulter counting.
(ii) Viability
You should indicate the percentage of cells that are alive, and 
how this has been determined. The percentage of apoptotic cells 
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should be stated if determined (indicate whether the starting 
material is fresh or frozen).
EXAMPLE: 95% viability as determined by trypan blue exclusion. 
5% of CD3+ T-cells had a phenotype indicating early apoptosis 
(7-AAD−, AnnexinV+) as measured by flow cytometry.
(2) Expansion/differentiation
The section describes the protocol that has been used for expan-
sion/differentiation of the isolated cells described in the previous 
section (Section 1). This process will hereafter be referred to as 
the expansion/differentiation process.
(a) Pre-culture conditions
The conditions under which the cells are kept after isolation but 
before starting the expansion/differentiation process (the fluid 
and type of container they are kept in, and at what temperature) 
should be described. The indication whether the starting material 
is fresh or thawed must be provided. You should also indicate the 
length of time between cell extraction and start of the expansion/
differentiation process.
EXAMPLE: isolated cells were placed in PBS with1% human serum 
albumin in a Falcon tube and kept at room temperature for up to 
30 min before starting the culture.
(b) Culture conditions
The conditions under which the cells are kept during the expan-
sion/differentiation process should be stated.
(i) Cell number
The number of cells used for the expansion/differentiation process 
should be stated, if different from numbers stated in Section 1ei.
EXAMPLE: in total 5 × 106 cells were put into culture
(ii) Cell concentration
The concentration of cells in the medium at the start of and 
throughout the expansion/differentiation process should be 
stated as cells/milliliter.
EXAMPLE: cells were put into culture at a concentration of 1 × 106 
cells/ml
(iii) Culture medium
The medium in which the cells are grown must be described, 
including its source, and whether it has any additives (e.g., antibi-
otics, inactivated serum), excluding the stimuli that are described 
later. If you use more than one type of medium, or refresh the 
medium during the culture, then you should describe that here.
EXAMPLE: X-VIVO15 (Lonza) supplemented with5% human 
male type AB-serum (Sigma)
(iv) Culture container
The physical container in which the culture is carried out. This 
can include tissue culture plates, tissue culture bags or flasks. You 
should state the type of container, size and manufacturer. You 
should also indicate the total cell culture volume per container or 
well, as well as the total number of containers used.
EXAMPLE: 20  ml of medium in a 100  ml MACS Good 
Manufacturing Practice (GMP) Cell Differentiation bag (Miltenyi 
Biotec); 1 bag
(v) Culture environment
Describe the physical environment in which the cells are kept 
during the expansion/differentiation process. This should 
include the temperature and CO2 concentration. You should note 
whether medium has been pre-warmed. You may describe the 
equipment used to maintain the culture environment.
EXAMPLE: 37°C, 5% CO2; Medium was pre-warmed to 37°C; 
Sanyo CO2 incubator
(c) Expansion/Differentiation protocol
The protocol that is used to expand/differentiate the cells 
should be described. This must include the type and source 
of cytokine(s) or other agent(s) added into the medium, and 
at what time point and concentration should be included. You 
should also state the total length of the culture period as well 
as the rounds of stimulation, rounds of culture change, and the 
number of cell passages.
EXAMPLE: rapamycin (final concentration of 100 nM; Rapamune®, 
Pfizer) was added on day 0, 2, 5, 7, and 9. IL-2 (final concentration 
of 500 IU/ml; Proleukin®, Novartis) was added on day 2, 5, 7, and 
9. Cells were harvested on day 12.
(d) Stimulus
It should be stated whether the cells are expanded/differenti-
ated polyclonally or in an antigen-specific manner or against an 
alloantigen. The protein(s), antibody(ies), accessory cells or other 
preparation(s) (e.g., antigen-presenting cells; APCs) with which 
the cells are stimulated must be named. You must describe the 
source of the preparation, concentration, and time point(s) at 
which it/they are added to the cell culture. Restimulation condi-
tions, if any, should also be stated.
EXAMPLE: cells were stimulated with CD3/CD28 MACS GMP 
ExpAct Treg Beads (Miltenyi Biotec) at a 4:1 bead:cell ratio. 
Cells were stimulated with CD40-activated allogeneic B  cells 
(30 Gy-irradiated) at a ratio of 10 B cells per nTreg cell.
(e) Storage
The conditions in which the cells are kept after completion of 
the expansion/differentiation process, but before being used 
in any subsequent experimental assay or treatment should be 
described. You should indicate the fluid and temperature in/at 
what the cells are being kept, as well as the length of time. You 
should indicate if cells are being frozen, and give details on the 
freezing and thawing procedures, including cell recovery and 
viability after thawing. You should also indicate if cells are taken 
out of their culture environment for any length of time during 
the expansion/differentiation process (e.g., if cells are frozen 
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before completion of this process, with the aim to resume it at a 
later date).
EXAMPLE: cells were kept in PBS 1% human serum albumin 
(Sigma) in a 50 ml Falcon tube at room temperature for a maxi-
mum of 2 h; Cells were frozen in FCS/10% DMSO.
(3) Cells after expansion/differentiation
This section describes the characteristics and state of the cells at 
the end of the expansion/differentiation process described in the 
previous section (Section 2).
(a) Phenotype
Characteristics of the cells at the end of their expansion/dif-
ferentiation, including their specificity and purity (e.g., as% 
of target cells) must be described. Where only a proportion 
of cells in the population display a characteristic, you should 
indicate the percentage. You should report on the stability of the 
phenotype and how you determined this. It should be indicated 
if the phenotype of the cells post-expansion was determined 
using fresh viable cells, or rather after a freeze–thaw cycle in a 
batched analysis.
(i) Cell surface and intracellular markers
A number of phenotypic markers help to define the Treg cel-
lular phenotype and specificity and are associated with distinct 
expression levels of surface and intracellular proteins. These 
markers are often characteristic of the transcriptional program of 
a cellular lineage and provide important information regarding 
the phenotypic stability and function of resulting cell products. 
You should describe: (1) what you measured, (2) the methodol-
ogy used for measurement (including information on reagents; 
if using mAbs, information on clonotype, conjugate and 
manufacturer) must be provided, (3) whether the cells received 
a stimulus and for how long before the measurement was car-
ried out, and (4) the method used to set marker or population 
positivity (e.g., fluorescence minus one method). You should use 
CD names when available (e.g., use CD127 instead of the alterna-
tive name IL-7Rα)—a full list of regularly updated CD numbers 
can be found on the website run by the HCDM (see footnote 
8) (human cell differentiation molecules). Otherwise, you may 
use databases, e.g., http://hla.alleles.org, for HLA alleles, Uniprot 
(see footnote 9) for proteins and ChEBI (see footnote 10) for 
non-protein organic molecules.
EXAMPLE: intracellular IFN-γ and IL-17 expression was measured 
by flow cytometry after 4 h incubation with 20 ng/ml PMA and 
1 µg/ml Ionomycin in the presence of 1 µl/ml GolgiPlug™ using the 
BD Cytofix/Cytoperm™ buffer set.
(ii) Secreted molecules
Indicate molecules that are, or are not, secreted by the cells. These 
include cytokines (e.g., IL-10) and other soluble mediators. You 
should describe: (1) what you measured, (2) if using mAbs, clone, 
conjugate, and source of all antibodies and reagents used must 
be provided, (3) the methodology used for the measurement, (4) 
cell density/ml of medium and plastic ware (e.g., 96 w round/
flat bottom), (5) when supernatant was collected for cytokine 
concentration measurement, and (6) whether the cells received 
a stimulus and for how long before the measurement was carried 
out.
EXAMPLE: soluble IFN-γ, TNF-α, IL-17, and IL-10 were measured 
in the cell culture supernatant at a cell density of 1 × 106 cells/ml by 
ELISA according to the manufacturers’ instruction.
(iii) Epigenetic modifications
Epigenetic modification relevant to the characteristics should be 
described if determined. Method of detection DNA demethyla-
tion should be clearly described.
EXAMPLE: the mean percentage of demethylated TSDR of the foxp3 
gene in the Treg population was 97% (Epiontis, Berlin, Germany).
(b) Functional assay
You should describe any characteristic of the cells that has been 
measured by a functional assay (type of assays). This could either 
be the response of the cells to some stimulus or the behavior of 
other biological entities after exposure to the cells. There should 
be a clear indication of how the percentage of suppression was 
calculated (i.e., include formula). Whenever accessory cells 
such as responder cells are included in the assay, source and 
phenotype should be described. Behavior such as expression/
production of molecules (described in Section 3a) does not need 
to be included.
EXAMPLE: proliferation-based suppression assay using CFSE 
labeled autologous CD4+CD25− responder cells; IFN-γ based sup-
pression assay
(c) Cell numbers
(i) Absolute cell number
You must indicate the total number of cells present at the end of 
the expansion/differentiation process, and how they have been 
counted and fold expansion should be included.
EXAMPLE: cell numbers were microscopically determined using 
C-Chip disposable counting chambers from NanoEnTek and fold 
expansion to day 0 was calculated.
(ii) Viability
You must indicate the percentage of cells that are alive and how 
this has been determined should be included.
EXAMPLE: 83% viability as determined by trypan blue exclusion
(d) Dosing
Whenever cells are transferred into an organism, details about 
dosing must be given. For clinical applications, information on 
the vehicle (solvent/medium) as well as intermediate components 
(trace amounts possible) must be given.
EXAMPLE: a single dose of 1 × 107 total nucleated cells per kilogram 
of body weight in 50 ml 0.9% NaCl was transfused i.v.
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(e) Quality control
If the cells were produced for a clinical trial, you must describe 
release criteria and any methods used to determine sterility, 
specificity, purity, and quality of the product.
(4) About the protocol
In this section, we describe the general features about the protocol 
as a whole.
(a) Regulatory authority
Information about whether the protocol being used has been 
validated or quality-controlled to standards agreed to by an 
external regulatory authority must be stated. You should state 
the name of this authority. Also you should state whether the 
protocol follows GMP.
EXAMPLE: Medicines and Health Regulatory Authority
(b) Purpose
You must describe the overall purpose of the production of the 
cells.
EXAMPLE: prevention of transplant rejection; Treatment of 
patients affected by Crohns’ disease.
(c) The relationship between the organism of origin of the cells 
and the target organism
You must state if the cell product is autologous/allogeneic/xeno-
geneic/syngeneic to the recipient.
EXAMPLE: patients receiving allogeneic kidney transplants and 
autologous Tregs. B6 mice receiving allogeneic (BALB/c xB6) heart 
transplants and syngeneic (B6) Tregs.
(d) Contact details
You must provide the name and contact information of the cor-
responding author(s).
(e) Citation
You should add information that your paper was written in 
accordance with the Minimum Information for T Regulatory 
Cells reporting guidelines.
13
Fuchs et al. Minimum Information about T Regulatory Cells
Frontiers in Immunology | www.frontiersin.org January 2018 | Volume 8 | Article 1844
aPPEnDiX B
(MITREG) Checklist
Must should May
(1) Cells at the start of procedure
(a) Essential information about the donor
(i) Species and strain
Species
Strain (if applicable)
(ii) Characteristics of the organism
Health
Age
Treatment/Environment
Individual identifier number
Source of purchase (if applicable)
(b) source of cell material
Organ, tissue, fluid, or blood product
Source (if applicable)
Quantity (volume, size, or weight)
Anti-coagulant (if applicable)
If using cryopreserved sample
Method and duration of storage
Initial cell counts
Ethical committee approval/written informed consent
(c) Cell separation process
(i) Cell handling and labeling
Cell extraction method
Tissue conditions between tissue retrieval and cell 
separation
Duration
Temperature
Container
Fluid
Cell labeling
Buffers and reagents (incl. source)
Cell suspension volume and concentration
Incubation temperature and duration
Washing steps
(ii) Cell separation equipment and process
Methodology
Equipment
Presence of target cells in starting material 
described
(d) Phenotype
For any of the below, indicate the percentage of cells 
displaying the characteristic (if known)
(i) Cell surface and intracellular markers
Must should May
Molecules measured [using cluster of differentiation 
(CD) names]
Details of reagents used and source (incl. mAb clone, 
fluorochrome)
Methodology
Stimulus and time of stimulation (if applicable)
Gating strategy to determine positive cells
(ii) Secreted molecules
Molecules measured
Details of reagents used (incl. mAb clone, conjugate) 
and source
Methodology
Cell density/ml of medium and type of tissue culture 
plate
Time point of supernatant collection
Stimulus and time of stimulation (if applicable)
(iii) Epigenetic modifications
Epigenetic modification relevant to the 
characteristics
(iv) Specificity
Specificity of the cells (polyclonal or antigen-specific)
Methodology used to obtain specificity
Methodology used to confirm specificity
(e) Cell numbers
(i) Absolute cell number
Total number of cells at the end of the isolation 
process
Methodology
(ii) Viability
Percentage of viable cells
Methodology
(2) Expansion/differentiation
(a) Pre-culture conditions
Storage conditions
Fluid
Type of container
Temperature
Fresh or thawed
Storage time
(b) Culture conditions
(i) Cell number
The total number of cells put into culture
(ii) Cell concentration
The number of cells per ml of medium at start of 
culture
(iii) Culture medium
Type(s) of medium
Source(s)
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Must should May
Additives (excluding agents to maintain/induce 
T regulatory cells)
Refreshment of the medium
(iv) Culture container
Type of container
Size
Manufacturer
Cell culture volume per container or well
Total number of containers or wells
(v) Culture environment
Temperature and CO2 concentration
Use of pre-warmed medium
Equipment
(c) Differentiation/tolerization protocol
Name of cytokine(s) or other agent(s) used
Concentrations
Time point(s) added to cell culture 
Total length of the culture period
Rounds of stimulation
Number of cell splitting
(d) stimulus
Polyclonal/antigen-specific/alloantigen
Stimulus (agent and/or accessory cell)
Source
Concentration
Time point(s) added to culture
Restimulation conditions (if applicable)
(e) storage
Storage time
Storage conditions
If fresh
Fluid
Container
Temperature
If cryopreserved
Freezing/thawing process
Freezing medium
Cell recovery and viability after thawing
Time point at which cells are stored if different to 
the end of the culture process
(3) Cells after expansion/differentiation
(a) Phenotype
For any of the below, indicate the percentage of cells 
displaying the characteristic (if known)
Must should May
Stability of the phenotype (if tested)
Phenotype tested on fresh or thawed cells
(i) Cell surface and intracellular markers
Molecules measured (using CD names)
Details of reagents used and source
Methodology
Stimulus and time of stimulation (if applicable)
Gating strategy to determine positive cells
(ii) Secreted molecules
Molecules measured
Details of reagents used and source
Methodology
Cell density/milliliter of medium and type of tissue 
culture plate
Time point of supernatant collection
Stimulus and time of stimulation (if applicable)
(iii) Epigenetic modifications
Epigenetic modification relevant to the  
characteristics
(b) functional assay
Response of the cells to a defined stimulus
Behaviour of other biological entities after exposure 
to the cells
If using accessory cells, describe phenotype and 
source
(c) Cell numbers
(i) Absolute cell number
Total number of cells at the end of the expansion 
process
Methodology
(ii) Viability
Percentage of viable cells
Methodology
(d) Dosing
Dose of cells transferred into organism (if  
applicable)
Vehicle (solvent/medium) and intermediate 
components (for clinical trials only)
(e) Quality control (for clinical trial only)
Specificity
Purity
Sterility
Potency
(4) about the protocol
(a) Regulatory authority
External authority that approved the protocol
Does protocol follow Good Manufacturing  
Practice?
15
Fuchs et al. Minimum Information about T Regulatory Cells
Frontiers in Immunology | www.frontiersin.org January 2018 | Volume 8 | Article 1844
Must should May
(b) Purpose
The disorder for which the cell treatment has been 
manufactured
(c) Relationship between the source organism for 
the cells and the target organism
Allogeneic/autologous/ xenogeneic/syngeneic
Must should May
(d) Contact details
Name and contact information of the corresponding 
author(s)
(e) Citation
Acknowledge the MITREG reporting guidelines
